Health Canada – Alysena Recall

Following the recall of the birth control drug, Alysena, Health Canada asked RSI to provide an analysis of the events that led to public criticism of the process.

The evaluation consisted of an analysis of the regulatory and procedural basis of the department’s responsibilities and powers, interviews of key personnel involved in the department’s response, and an examination of the timeline of the events.

RSI’s analysis led to the development of a set of recommendations that included changes to the department’s process for communicating with the public about drug problems and recalls, and the provision of increased regulatory powers for the department in future revisions of the relevant legislation.